The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk … Continue Reading
Read nowLong Ideas - A month after raking in more than $225M through a combination of debt and equity sales, InterMune’s (ITMN) 2012 financial results released Thursday contain little … Continue Reading
Read nowEducation - In my estimation, there have been approximately 114 PDUFA decisions relating to NDA/BLA and sNDA/sBLA’s in 2012. Of these, 97 applicants received drug approvals and … Continue Reading
Read nowResearch - The hope remains alive that Optimer (OPTR) will somehow power through a disappointing launch and increase prescription growth sufficiently to offset the 25% discount that … Continue Reading
Read nowLong Ideas - Just over a week has passed since our last report on Pharmacyclics (PCYC), in which we argued that the stock has solid upside potential based … Continue Reading
Read nowLong Ideas - Shares of Questcor Pharmaceuticals (QCOR) have started to rise to more realistic valuations in the new year (as PropThink expected), breaking $31 dollars on Tuesday … Continue Reading
Read nowLong Ideas - Shares of Chelsea Therapeutics (CHTP) opened sharply higher on news Wednesday that FDA has provided the company with a new pathway for approval of Northera. … Continue Reading
Read now
